DotLab is a personalized medicine company developing DotEndo, a non-invasive diagnostic test intended to detect endometriosis without requiring laparoscopic procedures. The test is physician-ordered through a lab and is explicitly not a genetic test. DotLab completed a Yale University-led validation study for DotEndo and positions the product as a better, cheaper, less painful alternative to current diagnostics. The company raised $10 million in Series A funding to bring the test to market. Investors in the round include CooperSurgical, Tiger Global Management, Luxor Capital Group and law firm Wilson Sonsini Goodrich & Rosati. Next steps for DotLab are to get the test into the hands of physicians so they recommend DotEndo to patients exhibiting symptoms.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2019